ArticleJournal of carcinogenesis2021
Ten-year survival outcome of breast cancer patients in India.
Article in Journal of carcinogenesis, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 10 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
10 citing papers in PubMed.
- Comparative Evaluation of Infrared Thermography and Mammography in the Detection of Breast Cancer.Cureus · 2026Article
- Whole-exome sequencing for identification of specific gene mutations in an Indian cohort of triple-negative breast cancer patients.Discover oncology · 2025Article
- From exclusion to inclusion: Analysis of patterns of follow-up in breast cancer.International journal of surgery protocols · 2025Article
- Article
- Ten-year survival in early-stage breast cancer patients in a comprehensive breast cancer care program in India.Frontiers in public health · 2025Article
- A protocol paper on the implementation of health care model to improve the survival of breast cancer patients in India.Therapeutic advances in medical oncology · 2025Article
- Survival Outcomes of Breast Cancer Patients in South India Over 20 Years.Asian Pacific journal of cancer prevention : APJCP · 2024Article
- The influence of chronic renal insufficiency on multi-therapeutic modalities for breast cancer: a single-center experience.Breast cancer (Tokyo, Japan) · 2024Article
- Ki 67: a Promising Prognostic Marker in Early Breast Cancer-a Review Article.Indian journal of surgical oncology · 2023Review
- Expanding the horizon for breast cancer screening in India through artificial intelligent technologies -A mini-review.Frontiers in digital health · 2022Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
introductionBreast cancer is the most frequently diagnosed cancer among women in India; however, there are no studies addressing long-term survival (10 years and above). This study sought to evaluate long-term oncological outcome among women with breast cancer treated with a curative intent. MATERIALS AND
methodsThis is a retrospective cohort analysis of 1301 breast cancer patients of all stages who had received primary treatment with curative intent from 2004 to 2010 at a single cancer institution of India.
resultsA total of 1301 breast cancer patients were available for final analysis. The median age was 51 years (range, 21-86 years). 70.25% of the patients had early breast cancer (EBC), 21.9% had locally advanced breast cancer, and 7.85% of the patients with de novo metastatic disease also underwent surgery. 56.5% of the patients had hormone-sensitive tumors, human epidermal growth factor receptor 2 over expression was seen in 17%, and triple-negative tumors accounted for 26.2% of the patients. The 5- and 10-year overall survival (OS) of the entire cohort was 79% and 66%, and the 5- and 10-year breast cancer-specific survival (BCSS) was 79% and 70%, respectively. OS and BCSS were 51% and 58%, respectively, at 15-year follow-up after primary cancer treatment. On multivariate analysis, the factors associated with prolonged survival were age ≤50 years, EBC, and treatment during the later period (2008-2010).
conclusionDifference between OS and BCSS was found to have an increasing trend during 10-15-year follow-up, the difference being 4% at 10 years and 7% at 15 years. Age ≤50 years, early-stage disease at presentation, and primary cancer treatment in later years (2008-2010) were favorable predictors for 10-year survival.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.